Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TNGX 
Tango Therapeutics Inc (TNGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: TNGX (4-star) is a STRONG-BUY. BUY since 10 days. Simulated Profits (-3.99%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.25
1 Year Target Price $13.25
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 318.84% | Avg. Invested days 34 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.30B USD | Price to earnings Ratio - | 1Y Target Price 13.25 |
Price to earnings Ratio - | 1Y Target Price 13.25 | ||
Volume (30-day avg) 8 | Beta 1.72 | 52 Weeks Range 1.03 - 11.20 | Updated Date 12/6/2025 |
52 Weeks Range 1.03 - 11.20 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -151.15% | Operating Margin (TTM) 26.15% |
Management Effectiveness
Return on Assets (TTM) -24.52% | Return on Equity (TTM) -51.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1170811789 | Price to Sales(TTM) 19.5 |
Enterprise Value 1170811789 | Price to Sales(TTM) 19.5 | ||
Enterprise Value to Revenue 17.61 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 134677094 | Shares Floating 80126499 |
Shares Outstanding 134677094 | Shares Floating 80126499 | ||
Percent Insiders 4.95 | Percent Institutions 97.34 |
Upturn AI SWOT
Tango Therapeutics Inc
Company Overview
History and Background
Tango Therapeutics, founded in 2017, is a biotechnology company focused on discovering and developing novel cancer therapies. They aim to overcome resistance mechanisms and address unmet needs in cancer treatment through the discovery of innovative drug candidates.
Core Business Areas
- Target Discovery: Identifies novel cancer targets through CRISPR-enabled functional genomics and other proprietary platform technologies.
- Drug Development: Develops small molecule therapeutics targeting the identified cancer targets. Focused on Synthetic Lethality.
- Clinical Programs: Runs clinical trials to evaluate the safety and efficacy of drug candidates.
Leadership and Structure
Barbara Weber serves as the President and CEO. The organizational structure involves research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- TNG908: A MTA-cooperative PRMT5 inhibitor, currently in Phase 1/2 clinical trials for MTAP-deleted cancers. Competitors include companies developing PRMT5 inhibitors (e.g., Pfizer, GSK) and other targeted therapies for MTAP-deleted cancers.
- TNG462: A CoREST Program Inhibitor, currently in Phase 1 clinical trials. Competitors include companies developing similar epigenetic modulators.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with significant unmet needs. Targeted therapies and immunotherapies are key growth areas.
Positioning
Tango Therapeutics focuses on synthetic lethality and discovering novel targets, aiming to differentiate itself through innovative approaches. They focus on cancers with defined genetic dependencies.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is hundreds of billions of dollars. Tango is positioned to capture a portion of this market by targeting specific genetic vulnerabilities in tumors, like MTAP deletions. Actual market capture depends on clinical success.
Upturn SWOT Analysis
Strengths
- Novel target discovery platform
- Experienced management team
- Strong intellectual property position
- Focus on high-value cancer targets
Weaknesses
- Early-stage clinical pipeline
- High research and development costs
- Reliance on successful clinical trial outcomes
- Limited revenue generation
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Positive clinical trial results
- Advancements in precision medicine
Threats
- Clinical trial failures
- Competition from other biotechnology companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- PFE
- GSK
- MRTX
- ARRY
Competitive Landscape
Tango's competitive advantage lies in its target discovery platform and focus on synthetic lethality. However, it faces competition from larger pharmaceutical companies with more resources and established products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline and partnerships.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of products. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for TNG908 and TNG462 and expanding its discovery pipeline.
Summary
Tango Therapeutics is an early-stage biotech firm with a promising target discovery platform and focus on synthetic lethality. Its future hinges on the success of its clinical trials, particularly TNG908 and TNG462. Competition from larger pharma companies poses a challenge, but strategic partnerships could accelerate growth. Its limited revenue generation makes it vulnerable.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (Yahoo Finance, MarketWatch, etc.)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tango Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-09-03 | President, CEO & Director Dr. Barbara L. Weber M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.tangotx.com |
Full time employees 155 | Website https://www.tangotx.com | ||
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.